Decreased plasma conc w/ potent P-gp, CYP2B6, CYP2C8 or CYP3A4 inducers eg, rifampicin, rifabutin, St. John's wort, carbamazepine, phenobarb, phenytoin & moderate P-gp or CYP inducers eg, oxcarbazepine, modafinil, efavirenz, rifapentine. Increased plasma conc w/ P-gp, BCRP, OATP, CYP2B6, CYP2C8 or CYP3A4 inhibitors. Monitor INR values w/ vit K antagonists. Decreased velpatasvir conc w/ antacids, H
2-receptor antagonists, PPI, efavirenz/emtricitabine/tenofovir disoproxil fumarate. Severe bradycardia & heart block w/ amiodarone. Increased digoxin, rosuvastatin conc. Increased bleeding risk due to dabigatran etexilate exposure. Increased tenofovir exposure. Monitor statins AR w/ other HMG-CoA reductase inhibitors.
Sign Out
